Experts from Quotient Sciences and NGT Biopharma Consultants will lead a deep dive into the technical hurdles of drug development, focusing on how physicochemical properties dictate the choice of enabling technologies. The session aims to provide a roadmap for selecting between methods like hot melt extrusion, spray drying, lipid-based systems, and particle size reduction to ensure clinical success.

Robert Cornog, Mark A. Krook, and Andrew Parker will present real-world examples of how a connected development model supports consistency from first-in-human studies through later stages. By aligning early formulation decisions with commercial readiness and manufacturing robustness, sponsors can avoid the costly pitfalls of late-stage reformulation. The event serves as a practical guide for balancing scientific rigor with the logistical demands of clinical supply chains.